We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Colchicine Inhibits Tumor Cell "Stickiness” Within Surgical Wounds

By HospiMedica International staff writers
Posted on 26 Aug 2008
A new study suggests that perioperative treatment with colchicine might decrease the incidence of secondary tumor formation due to pressure-induced cell implantation at the site of the surgical wound.

Researchers at the John D. More...
Dingell Veterans Affairs (VA) Medical Center (Detroit, MI, USA) and Wayne State University (Detroit, MI, USA) removed Co26 and Co51 colon cancer cells from one mouse, exposed them to high pressure in vitro (due to the fact that when colon cancer tumor cells are exposed to high pressure they exhibit an increased ability to stick to other cells), and then transplanted them into a second mouse that they monitored for the development of tumors at the site of the surgical wound. The researchers hypothesized that perioperative administration of colchicine, which prevents microtubule polymerization, could disrupt pressure-stimulated tumor cell adhesion to surgical wounds, and enhance tumor-free survival. The researchers found that mice treated with pressure-activated Co26 and Co51 cells from tumors preoperatively treated with colchicine in vivo displayed reduced surgical site implantation and significantly increased tumor-free survival compared with mice exposed to pressure-activated cells from tumors not pretreated with colchicine. The study was published in the August 14, 2008, issue of the Journal of Clinical Investigation.

"Our present results suggest the possibility that cytoskeletal perturbation, whether by colchicine or by some other agent, can alter the responsiveness of malignant cells to external forces, inhibiting the subsequent adhesion of shed tumor cells, and enhancing tumor-free survival,” concluded lead author Mark Basson, M.D., Ph.D. of the departments of surgery, anesthesiology, and anatomy and cell biology. "Because epithelial tumor cells of other types, including breast and head and neck cancer also increase adhesion in response to elevated extracellular pressure, our results may also have implications for malignancies other than colon cancer.”

Colchicine is a highly poisonous natural product and secondary metabolite that disrupts axoplasmic transport in neurons. Originally extracted from plants of the genus Colchicum (Colchicum autumnale, also known as meadow saffron or autumn crocus), it was used to treat rheumatic complaints and especially gout, and was prescribed for its cathartic and emetic effects. Its present medicinal use is mainly in the treatment of gout, and can also be used as initial treatment for pericarditis and preventing recurrences of the condition.

Related Links:
John D. Dingell VA Medical Center
Wayne State University


Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Semi‑Automatic Defibrillator
Heart Save AED (ED300)
VTE Prevention System
Flowtron ACS900
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.